India and the United States have agreed to step up coordinated action against evolving narcotics threats following a high-level bilateral meeting here last week. The Narcotics Control Bureau (NCB) hosted the second India-United States Drug Policy Executive Working Group Meeting on November 2-3, marking a fresh push to disrupt transnational drug networks and protect pharmaceutical supply chains.
Director General, NCB Anurag led the Indian delegation, and the US side was led by Debbie Seguin, Acting Deputy Director, Office of National Drug Control Policy (ONDCP). Under the India-US Drug Policy Framework, they reviewed the current level of cooperation. They identified several areas where they could go further: intelligence sharing, joint law enforcement, precursor chemicals, pharmaceutical supply chain integrity, and demand
reduction.
Officials have stressed the importance of continued institutional engagement and a much faster flow of actionable intelligence to deal with synthetic drugs and other emerging threats. There was also agreement on the need to broaden the exchange of best practices on specific targeted enforcement issues so the dialogue can produce tangible results much more rapidly.
DG, NCB used the platform to lay out India’s Vision Roadmap 2026-2029, prepared under the aegis of PM Narendra Modi and the leadership of Union Home Minister Amit Shah. The roadmap is intended to guide India’s long-term strategy on drug trafficking and abuse and aligns with the international partnerships India is in a position to forge.
US officials have focused on framing the partnership in operational terms. ONDCP Director Sara Carter said the Executive Working Group and the bilateral efforts are essential to disrupting transnational trafficking networks and stopping the diversion of synthetic drugs and chemical precursors into the global market. US Ambassador to India Sergio Gor made the connection to the wider policy objectives, pointing out that President Trump has made it very clear that the protection of our communities starts with securing our borders and cutting off the illicit drug networks at the source.
“India and the US aren’t just talking about cooperation; we’re delivering tangible operational results in the form of precursor chemical interdiction, securing our commercial supply chains and the dismantling of the cartels that are exploiting them,” Gor said. He added that when the two law enforcement communities work together with speed and trust, the families of both the US and India are better protected.
The meeting takes place in the context of growing global concern about synthetic opioids, designer precursors and the misuse of legitimate pharmaceutical supply chains. For India, a major producer of generic medicines and chemical intermediates, supply chain integrity is especially important. For the US, the issue of stopping the flow of precursors into the illicit fentanyl and other synthetic production streams is a very high priority indeed.
By locking in concrete next steps on intelligence sharing and precursor controls, the two countries are looking to close gaps traffickers have exploited. The working group will remain the main mechanism for translating high-level commitments into practical action on the ground, with further best-practice exchanges due in the months ahead.
The deal clearly signals that both New Delhi and Washington see the drug threat as a shared security issue that requires closer operational alignment, not just periodic consultation.